GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » Piotroski F-Score

Innovative MedTech (Innovative MedTech) Piotroski F-Score : 6 (As of May. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Innovative MedTech has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Innovative MedTech's Piotroski F-Score or its related term are showing as below:

IMTH' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 6

During the past 13 years, the highest Piotroski F-Score of Innovative MedTech was 6. The lowest was 3. And the median was 5.


Innovative MedTech Piotroski F-Score Historical Data

The historical data trend for Innovative MedTech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative MedTech Piotroski F-Score Chart

Innovative MedTech Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Jun20 Jun21 Jun22 Jun23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A 3.00 4.00

Innovative MedTech Quarterly Data
Oct13 Jan14 Apr14 Jul14 Oct14 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 4.00 6.00 6.00

Competitive Comparison of Innovative MedTech's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Innovative MedTech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative MedTech's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innovative MedTech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Innovative MedTech's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -0.8 + -0.871 + -0.165 + -0.188 = $-2.02 Mil.
Cash Flow from Operations was 0.068 + -0.006 + -0.035 + -0.134 = $-0.11 Mil.
Revenue was 0.477 + 0.443 + 0.481 + 0.433 = $1.83 Mil.
Gross Profit was 0.477 + 0.443 + 0.481 + 0.433 = $1.83 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(4.501 + 4.512 + 4.45 + 4.571 + 4.33) / 5 = $4.4728 Mil.
Total Assets at the begining of this year (Dec22) was $4.50 Mil.
Long-Term Debt & Capital Lease Obligation was $0.67 Mil.
Total Current Assets was $0.30 Mil.
Total Current Liabilities was $3.80 Mil.
Net Income was 0.078 + -17.679 + -1 + -0.977 = $-19.58 Mil.

Revenue was 0.292 + 0.359 + 0.384 + 0.42 = $1.46 Mil.
Gross Profit was 0.292 + 0.359 + 0.384 + 0.42 = $1.46 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(4.793 + 4.988 + 4.8 + 4.587 + 4.501) / 5 = $4.7338 Mil.
Total Assets at the begining of last year (Dec21) was $4.79 Mil.
Long-Term Debt & Capital Lease Obligation was $0.81 Mil.
Total Current Assets was $0.33 Mil.
Total Current Liabilities was $5.59 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Innovative MedTech's current Net Income (TTM) was -2.02. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Innovative MedTech's current Cash Flow from Operations (TTM) was -0.11. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-2.024/4.501
=-0.44967785

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-19.578/4.793
=-4.08470686

Innovative MedTech's return on assets of this year was -0.44967785. Innovative MedTech's return on assets of last year was -4.08470686. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Innovative MedTech's current Net Income (TTM) was -2.02. Innovative MedTech's current Cash Flow from Operations (TTM) was -0.11. ==> -0.11 > -2.02 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.668/4.4728
=0.14934717

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.813/4.7338
=0.17174363

Innovative MedTech's gearing of this year was 0.14934717. Innovative MedTech's gearing of last year was 0.17174363. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=0.298/3.8
=0.07842105

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=0.326/5.588
=0.0583393

Innovative MedTech's current ratio of this year was 0.07842105. Innovative MedTech's current ratio of last year was 0.0583393. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Innovative MedTech's number of shares in issue this year was 21.157. Innovative MedTech's number of shares in issue last year was 21.157. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.834/1.834
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.455/1.455
=1

Innovative MedTech's gross margin of this year was 1. Innovative MedTech's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1.834/4.501
=0.40746501

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=1.455/4.793
=0.3035677

Innovative MedTech's asset turnover of this year was 0.40746501. Innovative MedTech's asset turnover of last year was 0.3035677. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Innovative MedTech has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Innovative MedTech  (OTCPK:IMTH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Innovative MedTech Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative MedTech (Innovative MedTech) Business Description

Traded in Other Exchanges
N/A
Address
2310 York Street, Suite 200, Blue Island, IL, USA, 60406
Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: the RX Vitality digital wallet and health care app.
Executives
Merle Griff officer: Chief Executive Officer 2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner 10 percent owner 70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt director, 10 percent owner, other: Chairman of the Board 2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman 10 percent owner 280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts 10 percent owner 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman director, 10 percent owner, officer: President & CEO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc. 10 percent owner 881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine director, officer: CFO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari director, officer: COO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz director 280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo director, officer: President 3163 KENNEDY BLVD, JERSEY CITY NJ 07306